Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo

Enterovirus infections can cause hand, foot, and mouth disease (HFDM), aseptic meningitis, encephalitis, myocarditis, and acute flaccid myelitis, leading to death of infants and young children. However, no specific antiviral drug is currently available for the treatment of this type of infection. Th...

Full description

Bibliographic Details
Published in:	Viruses
Main Authors:	Yuexiang Li, Miaomiao Liu, Yunzheng Yan, Zhuang Wang, Qingsong Dai, Xiaotong Yang, Xiaojia Guo, Wei Li, Xingjuan Chen, Ruiyuan Cao, Wu Zhong
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Subjects:	molnupiravir EIDD-1931 enterovirus antiviral
Online Access:	https://www.mdpi.com/1999-4915/14/6/1142

Similar Items

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
by: Mohd. Imran, et al.
Published: (2021-09-01)

The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
by: Lina Kamal, et al.
Published: (2022-05-01)

Ecotoxicological data of selected antiviral drugs acting against SARS-CoV-2: Aliivibrio fischeri bioluminescence inhibition, Daphnia magna immobilization, and comparison with in silico predictions
by: Indra Bartels, et al.
Published: (2025-06-01)

Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis
by: Huzaifa Ahmad Cheema, et al.
Published: (2024-06-01)

Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression
by: Evelyn J. Franco, et al.
Published: (2023-05-01)

Molnupiravir: From Hope to Epic Fail?
by: Daniele Focosi
Published: (2022-11-01)

EIDD-2801 resists to infection and co-infection of SARS-CoV-2 and influenza virus
by: Bingshuo Qian, et al.
Published: (2025-04-01)

A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants
by: Ching-Wen Chang, et al.
Published: (2022-06-01)

Unlicensed Molnupiravir is an Effective Rescue Treatment Following Failure of Unlicensed GS-441524-like Therapy for Cats with Suspected Feline Infectious Peritonitis
by: Meagan Roy, et al.
Published: (2022-10-01)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
by: Ashley Jia Wen Yip, et al.
Published: (2022-06-01)

Pavao Tekavčić (1931 - 2007)
by: Mitja Skubic
Published: (2007-12-01)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
by: Yuan Bai, et al.
Published: (2022-04-01)

Ks. Józef Rokoszny (1870-1931)
by: Walenty Wójcik
Published: (1965-03-01)

Phase I Pharmacokinetics Study of Oral Administration of Esperavir® (INN: Molnupiravir) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2024-03-01)

BIOEQUIVALENCE STUDY OF GENERIC MOLNUPIRAVIR IN HEALTHY VOLUNTEERS
by: V. B. Vasilyuk, et al.
Published: (2023-02-01)

La educación en tres momentos constitucionales (1812, 1931, 1978)
by: Ignacio Torres Muro
Published: (2025-10-01)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
by: Michela Pontolillo, et al.
Published: (2022-09-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

«In memoriam» professor doctor Antonio Eiras Roel (1931-2017)
by: Ofelia REY CASTELAO
Published: (2017-12-01)

Can Tremor Be a Rare Side Effect Related to Molnupiravir?
by: Sinan MERMER, et al.
Published: (2022-11-01)

Efficacy and safety of molnupiravir in adult outpatients with COVID-19
by: Natalia Y. Pshenichnaya, et al.
Published: (2023-06-01)

Degree-Based and Neighborhood Degree Sum-Based Entropy Measures of Molnupiravir
by: Shibsankar Das, et al.
Published: (2025-06-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Reciprocal Impact of Molnupiravir and Favipiravir Monocomponents of the Combination Drug on Each Other's Pharmacokinetics in a Phase I Clinical Trial
by: T. N. Komarov, et al.
Published: (2024-03-01)

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro
by: Zi-Xin Huang, et al.
Published: (2023-06-01)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
by: Clara Weil, et al.
Published: (2023-08-01)

Interaction between warfarin and molnupiravir in a patient with coronavirus disease 2019 infection
by: Hikari Mizutani, et al.
Published: (2022-01-01)

Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19
by: E. V. Shipaeva, et al.
Published: (2022-12-01)

Full factorial design assisted RP-UHPLC method development and study of stressed degradation of molnupiravir
by: Omar Faruk, et al.
Published: (2024-01-01)

Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study
by: Ivana I Gmizic, et al.
Published: (2024-05-01)

GS-441524 and molnupiravir are similarly effective for the treatment of cats with feline infectious peritonitis
by: Okihiro Sase, et al.
Published: (2024-07-01)

Leucoverdazyls as Novel Potent Inhibitors of Enterovirus Replication
by: Alexandrina S. Volobueva, et al.
Published: (2024-05-01)

In memoriam: Prof., dr. sc. Franc Vodopivec, 1931 – 2021
by: Ilija Mamuzić
Published: (2021-01-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

De Alessandri a Ibáñez: las relaciones económicas entre Chile y España en los años veinte (1920-1931)
by: Juan Luis Carrellán Ruiz
Published: (2015-01-01)

Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
by: Masahiro Kimata, et al.
Published: (2023-03-01)

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
by: Matthew G. Johnson, et al.
Published: (2024-03-01)

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
by: Henrik Berg Rasmussen, et al.
Published: (2023-10-01)

Role of Enterovirus ECHO 30 as the etiological agent of enterovirus infection in the North-West of Russia in 2013
by: M. A. Bichurina, et al.
Published: (2014-10-01)

Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders
by: Ting-Hui Liu, et al.
Published: (2024-07-01)